This live web event has ended. Thank you for attending.
We invite you to join our live discussion looking how can intrinsic molecular subtypes guide therapeutic decisions for breast cancer patients. The presentations will be supported by reports based discussions with Pr Frédérique Penault-Llorca, Pr Gilles Freyer and Dr Olivier Tredan.
Frédérique Penault-Llorca, MD, PhD, graduated as a medical specialist in pathology in 1993 and in oncology in 1995. Also, in 1995, she received a PhD from the Université d’Aix-Marseille II in cellular biology and microbiology, on the topic of HER2. Frédérique Penault-Llorca is currently professor of pathology at the University of Clermont-Ferrand, CEO of the Comprehensive Regional Cancer Institute Centre Jean PERRIN, Clermont-Ferrand, France, deputy director of the research team INSERM 1240 IMoST, and head of the Molecular Biology Plateform at Centre Jean Perrin. She serves as vice-president of the UNICANCER group and chairs of the Immuno-Oncology group at UNICANCER R&D. She is a member of several pathology and oncology societies, with her main areas of expertise being female cancers. She co-chairs the French breast cancer guidelines of Nice-St Paul. Frédérique Penault-Llorca has conducted various biomarkers-based research studies in breast, lung, digestive tract, prostate and thyroid cancer in relation to response to targeted therapies and immunotherapies. Frédérique Penault-Llorca has participated to more than 469 peer-reviewed publications and several books on female cancers and pathologic testing methods and issues.
Dr Gilles Freyer is a French professor, oncologist and medical professional who has specialised in the field of gynaecological cancers. He is currently head of the Department of Medical Oncology and Vice-Dean of the University of Lyon. He is also the current Medical Director of the Cancer Institute of the Hospices Civils de Lyon. He is known for having been the President of the cooperative group GINECO (Groupe d'Investigateurs National des Etudes des Cancers Ovariens et du sein) from 2013. He was also a member of the International Scientific Committee of INCa (French National Cancer Institute). Professor Freyer is also known for being the President of the Monaco Age Oncologie and the Co-President of the Biennale Monégasque de Cancérologie.
Freyer obtained his MD in 1994 and specialised in medical oncology the following year. He then obtained a degree in clinical pharmacology and psychophysiology at the University of Lyon I in 1995-96. In 1996, he obtained a master's degree in human biology from the same University. He also specialised in bioethics at the University of Paris in 1997. He obtained his PhD in Population Pharmacokinetics in 2000 at the University of Lyon.
Dr. Olivier Trédan obtained his medical degree
in 2004; he received his PhD from the Claude Bernard University, Lyon in 2009. He
was Fellow of the Royal College of Physicians of Canada (FRCPC), during a
post-doc period (University of Toronto / Princess Margaret Cancer Center,
Toronto, ON, Canada). He is currently medical oncologist in the Department of
Medical Oncology at the Centre Léon Bérard, Lyon, France. He serves as Chair of
this Department since 2020.
He is staff physician and senior scientist (co-director
of the “Endocrine resistance, methylation and breast cancer” team at the Centre de Recherche en Cancérologie de Lyon,
UMR INSERM 1052). He is involved in the Breast Cancer Translational Research
Program at the Centre Léon Bérard. He has a large clinical activity and leads
many clinical and translational research projects on breast and gynecological cancers.
He is an active member of the French Breast
Cancer Group (UCBG) and the GINECO group. He has published >180
peer-reviewed articles in the area of breast / gyne cancers.
Dr. P. Kelly Marcom joined Veracyte in June, 2021 as the
Medical Director for Breast Cancer. He
came from Duke University, where he was Professor of Medicine and Director of
the Duke Multidisciplinary Breast Cancer Program. After undergraduate education at Texas
A&M University and medical school at Baylor College of Medicine, he moved
to Duke University for postgraduate training in internal medicine and
hematology/oncology, completing training in 1995. He joined the medical oncology faculty in
1995 doing basic research on cell cycle control and as a member of the breast
group in 1997 as a clinical and translational researcher. He established the Duke Hereditary Cancer
Clinic in 1998 and led it until 2016, when he became the breast program
director. Nationally, he has been a
member of the National Comprehensive Cancer Network guidelines panels for
Breast Cancer and Breast/Ovarian Genetics and served as track leader for the
Cancer Genetics Education planning committee for ASCO in 2017. He was an active member of many
clinical/translational programs, including CALGB, the Translational Breast
Cancer Research Consortium, and Duke Breast Cancer SPORE grants. His research interests have focused on
improving the management of breast cancer with an overall theme of using
genetic and genomics to guide personalized risk assessment and treatment.